Atlas Trials

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Clinical trial NCT03832361 · RECRUITING

Trial details

NCT number
NCT03832361
Sponsor
Alessandro Santin
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Endometrial Cancer
Start date
2020-07-15
Primary completion
2026-10-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.